OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer	517
Issue Information	437
The economics of advanced and unresectable hepatocellular carcinoma	232
New standard of care for multiple myeloma?	174
Best of both worlds? Linking comprehensive and noncomprehensive cancer centers	170
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis	148
Potential of circulating tumor DNA to refine immunotherapy	115
Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation	95
Reply to “Enhancing the role of social work in managing cancer risks among LGBTQ+ populations” and “The urgency of systematically acquiring sexual orientation and gender identity data to ensure equity	85
	81
Accelerated approval of multiple myeloma therapies	79
	76
Issue Information	76
	74
Issue Information	72
Issue Information	71
	66
New test for detecting cervical adenocarcinoma	64
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient‐centere	63
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	62
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer	62
Sharp rise in esophageal cancer and Barrett esophagus seen in middle‐aged people	61
Development and validation of a machine‐learning–based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospect	60
Updates on research and management of gastrointestinal stromal tumors in China	59
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non‐Indigenous men in a universal health care system	58

What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?	56
Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality	55
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”	51
Updated American Cancer Society lung cancer screening guidelines	49
Erratum to “Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study”	49
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia	49
Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”	49
Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”	49
Epistemic equity in oncology: Opportunities to leverage patient‐centric implementation in clinical trial design	48
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53	48
Correction to “Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly”	48
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders	45
Characteristics of clinical trials of new oncology drugs approved in China	45
What enhanced recovery means for patients with cancer undergoing surgery	45
Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer	44
Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy	44
Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion	44
Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana	43
The role of relative advantage for development of sequencing‐based diagnostics for pediatric cancer in low‐ and middle‐income countries	43